Is Prozac (Fluoxetine) Safe with Ketamine?

If you're on Prozac (fluoxetine) and considering at-home ketamine therapy, the combination is safe and routine. Prozac is one of the most prescribed antidepressants in the country and has been combined with ketamine in countless real-world TRD patient encounters without specific safety signals. Two fluoxetine-specific clinical wrinkles deserve a brief explanation because they make Prozac a little different from other SSRIs: it inhibits a liver enzyme that handles ketamine, and its active metabolite has the longest half-life in the SSRI class. Neither changes the verdict, but both shape the conversation slightly.

Why the question matters less for Prozac than for newer SSRIs

Prozac has been on the market since 1987 and has decades of accumulated clinical experience. Its safety profile in combination with virtually every commonly co-prescribed medication is well-mapped, and ketamine specifically has been used alongside fluoxetine for decades in research settings, depression-treatment trials, and real-world TRD practice. The published case literature does not contain serotonin syndrome events from at-home ketamine plus standard-dose Prozac, and the dedicated systematic reviews on ketamine pharmacodynamic interactions treat the SSRI plus ketamine combination as settled clinical practice.

The Curran and colleagues 2026 outcomes study in the Journal of Clinical Psychiatry analyzed 332 patients on ketamine or esketamine grouped by concurrent antidepressant class; SSRIs (including fluoxetine) showed no differential outcomes versus other antidepressant classes or no concurrent antidepressant. The Veraart and colleagues 2021 systematic review (International Journal of Neuropsychopharmacology, PMID 34170315) explicitly excluded the SSRI plus ketamine combination from analysis as "demonstrated irrefutably" safe. The Alnefeesi and colleagues 2022 real-world meta-analysis (Journal of Psychiatric Research, PMID 35688035) pooled 2,665 TRD patients, most on prior antidepressants with fluoxetine among the most common, and reported 45% response and 30% remission with ketamine added on top.

So at the level of "is it safe to combine," the answer for Prozac is the same as for any standard SSRI: yes, routinely.

The CYP3A4 inhibition note

Fluoxetine and its active metabolite norfluoxetine are described in the pharmacokinetics literature (Hoffelt and Gross, Mental Health Clinician 2016, PMID 29955445) as moderate inhibitors of CYP3A4 (and strong inhibitors of CYP2D6, less relevant here). Ketamine is metabolized in the liver primarily by CYP3A4 and CYP2B6 in a stepwise process that produces norketamine and several downstream metabolites. The theoretical question is whether fluoxetine's CYP3A4 inhibition could slow ketamine clearance and produce higher or longer-lasting ketamine plasma levels than expected.

In clinical practice at at-home sublingual ketamine doses, this rarely matters. The dose ranges we use are well below thresholds where CYP-mediated kinetics make a clinically meaningful difference, the inhibition is moderate rather than strong, and norketamine (the principal active metabolite) has its own pharmacologic activity that further buffers any kinetic shift. Some patients on Prozac report a subjectively longer-lasting ketamine experience than they'd expect at their dose, which is consistent with the theoretical PK profile, but we don't routinely dose-adjust ketamine based on fluoxetine co-prescription. The interaction is real on paper and worth knowing about; it doesn't drive a different clinical protocol.

The interaction matters more in two specific scenarios. First, IV ketamine at higher doses (where the absolute exposure is larger to begin with). Second, patients on Prozac plus other CYP3A4 inhibitors (azole antifungals, macrolide antibiotics, certain HIV protease inhibitors). For at-home sublingual ketamine in a typical TRD patient on Prozac monotherapy, the theoretical PK slowing is not actionable.

The long-half-life note

Prozac's long half-life is the most clinically distinctive feature among SSRIs. Fluoxetine itself has a half-life of 2 to 4 days; its active metabolite norfluoxetine has a half-life of 7 to 9 days. Practically, this means a few things for ketamine intake.

After starting or changing a Prozac dose, the medication continues to reach steady-state plasma levels for 4 to 6 weeks before settling, longer than the 2 to 3 weeks for shorter-acting SSRIs. We ask for 8 to 10 weeks of dose stability before adding ketamine on top, rather than the standard 6 weeks we'd use for Zoloft or Lexapro. This isn't a safety question; it's a clinical-clarity question. We want to be able to tell what's working and what isn't during the first weeks of ketamine, and a not-yet-settled fluoxetine dose changing in the background makes that harder.

Discontinuing or tapering Prozac also unfolds over a longer window than other SSRIs. Patients sometimes report that they didn't notice withdrawal effects from stopping Prozac the way they did from stopping Zoloft or Paxil; that's because fluoxetine's long half-life produces an automatic slow taper. The flip side is that if you do stop Prozac and need to switch to a different serotonergic agent (most importantly an MAOI), the standard washout window is 4 to 6 weeks rather than the 14 days adequate for shorter-acting SSRIs. This is part of why MAOIs are operationally avoided in our at-home model regardless of which SSRI a patient is coming off.

If you're stable on Prozac and not changing anything, none of this is relevant to your intake. If you're in the middle of a dose change, recently started Prozac, or considering switching, mention it at intake and we'll calibrate timing.

What we do at intake

When a patient is on Prozac, our intake process for ketamine is the same as for any patient with a few brief Prozac-specific confirmations:

The dose and how long you've been at that dose. Stable on the same dose for 8 weeks or more is the most common picture and doesn't trigger any timing concerns.

Whether there have been recent dose changes in the past 8 to 10 weeks. If yes, we'll usually want a bit more stability before adding ketamine on top.

Other concurrent serotonergic medications. The combination patterns that matter for serotonin syndrome risk are not "Prozac plus ketamine" but "Prozac plus tramadol plus a triptan" or "any SSRI plus an MAOI." We screen for the polypharmacy patterns.

Other CYP3A4 inhibitors. Rarely an issue but worth noting if you're on an azole antifungal, certain antibiotics, or certain HIV medications concurrently with Prozac.

For most patients on stable Prozac, this is a five-minute conversation and we proceed with standard ketamine onboarding.

High-dose Prozac (60-80 mg/day)

Some patients have escalated to higher doses of Prozac over time, often in the 60 to 80 mg/day range, which is at or near the upper end of the typical adult dosing range. This is most common in treatment-resistant depression and in OCD treatment specifically (Prozac is FDA-approved for OCD at doses up to 80 mg/day). These patients are exactly who at-home ketamine is designed for.

The high dose does not change our verdict. We confirm you've been stable at the high dose for at least 8-10 weeks and review for additional serotonergic medications that could stack the load. Many of our patients in the 40-80 mg Prozac range proceed with standard onboarding and respond to ketamine on the same trajectory as patients on lower doses.

Tapering: a separate conversation

A common question is whether ketamine can be a bridge to coming off Prozac. The answer for some patients is yes, for others no. Prozac is unusual among SSRIs because the long half-life means tapering is essentially self-managing once you stop, and many patients tolerate it better than they expected. If tapering is on the table after stable improvement on ketamine, the conversation is different from tapering a shorter-acting SSRI, mainly easier in practice. As with any antidepressant taper, the decision belongs between you and your prescribing physician on its own clinical merits, not as a precondition for ketamine.

Bottom line

Prozac at standard doses is one of the safest SSRIs to combine with at-home ketamine therapy. The SSRI plus ketamine evidence base applies in full, there's no required washout, no special precaution beyond standard intake review, and the published case literature contains no serotonin syndrome events from this combination at therapeutic doses. The two fluoxetine-specific wrinkles (moderate CYP3A4 inhibition with theoretical ketamine PK slowing, and the long active-metabolite half-life requiring slightly longer dose-stability windows) are worth knowing about but rarely change anything operationally. Most patients on Prozac proceed with standard ketamine onboarding and respond on the same trajectory as patients on any other SSRI.